Advanced Filters
noise

Heerlen, Netherlands Clinical Trials

A listing of Heerlen, Netherlands clinical trials actively recruiting patients volunteers.

Found 102 clinical trials
P Patrinos, Prof.

Empowering Patients to Improve Safety in Polymedication

Rationale: In current clinical practice, polypharmacy and patient empowerment are critical yet often overlooked. Polypharmacy, the chronic use of five or more drugs, poses risks such as adverse drug reactions and decreased medication adherence, especially in elderly and multimorbid patients. Despite the interconnected nature of drug-drug and drug-gene pro inter-actions, …

18 years of age All Phase N/A
C Cornelia Erfurt-Berge, Dr.

Post-Marketing Surveillance of Vliwazell® Prowound Dressing

This PMCF study is conducted to confirm the effectiveness and safety of the wound dressing Vliwazell® Pro. The aim of the study is to validate the performance of Vliwazell® Pro within its intended purpose and certified indications during routine use, and to gather additional safety data. The study will examine …

18 years of age All Phase N/A
M Maria Dr. Aetou, Dr.

Smoking Cessation Before Bronchoscopy or CT-guided Puncture

Nicotine is the most common preventable cause of death and is responsible for over seven million deaths worldwide. If current trends continue, tobacco will kill more than eight million people worldwide every year by 2030. Smoking tobacco products is the most important risk factor for the development of lung cancer. …

18 years of age All Phase N/A
J Jordy Mongula, Doctor

Effect of Honey For CIN II

The following hypothesis is tested: Medical grade honey in CIN II causes a higher clearance of the hr-HPV virus and an increase in the normalization of CIN II lesions compared to expectant management.

18 - 40 years of age Female Phase 1/2
M Myrthe MG Moermans, MD

Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis

5-Fluorouracil (5FU) is proven to be the most effective therapy in field directed treatment for AK, with Jansen et al. reporting a 1-year probability of treatment success of 74.7%. However, treatment with 5FU is associated with side effects, like erythema, itching, a burning sensation and crusting, and a burdensome dosing …

18 years of age All Phase 4
A Alexander J.J. Ijsselmuiden, MD, PhD

Use of Mechanical Left ventricuLar Unloading in Complex Higher-risk Indicated Procedures

If there is a narrowing or blockage in the coronary arteries of the heart, the cardiologist may choose to treat this blockage. This is called percutaneous coronary intervention (PCI), which involves both balloon angioplasty and the placement of a stent. PCI is a commonly performed and safe procedure. However, in …

18 years of age All Phase N/A
M Martin Mynarek, MD

International HIT-MED Registry (I-HIT-MED)

The I-HIT-MED registry registers clinical of children and adults with medulloblastoma, ependymoma, pineal tumours, or choroid plexus tumours in Germany and other countries that fulfil national ethic requirements for participation in this registry. These tumours are rare diseases, and many patients are treated outside of clinical trials. The I-HIT-MED registry …

years of age All Phase N/A
C Christian Stoppe, PD Dr. med.

Development of a Biological Database in the Field of Operative Intensive Care

The storage and use of biomaterial samples is an important requirement for accompanying research and the acquisition of new knowledge to improve prognosis and therapy. Biobanking is explicitly recommended in official guidelines. In order to preserve the biomaterial, the patient must consent to the removal, transfer and storage of the …

18 years of age All Phase N/A

Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).This study will assess how effective upadacitinib is in treating UC. Upadacitinib (RINVOQ) is an approved drug for treating UC. Approximately 400 adult participants who are …

18 years of age All Phase N/A

BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment

The presence of a BRAFV600E mutation is a marker of poor prognosis in patients with mCRC and associated with a median overall survival (mOS) of approximately 12 to 14 months compared to 20 to 25 months for patients with BRAF wild-type tumours. After 1st line therapy, treatment outcomes with standard …

18 years of age All Phase N/A

Simplify language using AI